What it's sold for

Weight loss
Blood sugar control
Metabolic health

What has actually been tested

Obesity
Overweight
Healthy
Type 2 Diabetes
Diabetes Mellitus, Type 2
Obstructive Sleep Apnea
Atherosclerotic Cardiovascular Disease (ASCVD)
Body Composition

Is it studied for what it's sold for?

Each claim below is matched against the condition and title fields of every registered trial. Not listed means no trial names it as a studied condition — not that it has been disproven, and not that no trial touches it indirectly.

Studied Weight loss

Not listed Blood sugar control

Studied Metabolic health

Every trial on record

Every registered human study we can find for Retatrutide. Click any ID to read the original record — we would rather you checked us than trusted us.

Trial ID	Title	Condition	Phase	Status	Enrolled
NCT07467447	Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight	Obesity	Phase 2	Recruiting now	300
NCT07165028	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	Metabolic Dysfunction-Associated Steatotic Liver Disease	Phase 3	Recruiting now	4500
NCT07226947	Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment	Obesity, Body Composition	Not phased	Recruiting now	100
NCT06313528	A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943	Obesity	Phase 1	Completed	85
NCT03841630	A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants	Healthy	Phase 1	Completed	45
NCT05445232	A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants	Obesity	Phase 1	Completed	32
NCT05931367	A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee	Obesity, Overweight	Phase 3	Completed	445
NCT06003465	A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices	Healthy	Phase 1	Completed	57
NCT05611957	A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function	Healthy, Renal Insufficiency	Phase 1	Completed	29
NCT04143802	A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)	Diabetes Mellitus, Type 2	Phase 1	Completed	72
NCT04867785	A Study of LY3437943 in Participants With Type 2 Diabetes	Type 2 Diabetes	Phase 2	Completed	281
NCT05916560	A Study of LY3437943 in Participants With Impaired and Normal Liver Function	Healthy, Hepatic Insufficiency	Phase 1	Completed	43
NCT06808802	To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants	Healthy	Phase 1	Completed	30
NCT05959096	A Study of LY3437943 in Healthy Participants With a High Body Mass Index	Healthy	Phase 1	Completed	85
NCT05548231	A Study of LY3437943 in Chinese Participants With Obesity Or Overweight	Overweight, Obesity	Phase 1	Completed	32
NCT06039826	A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese	Overweight	Phase 1	Completed	46
NCT05936151	A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	Overweight or Obesity, CKD	Phase 2	Completed	146
NCT06354660	Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)	Diabetes Type 2	Phase 3	Completed	537
NCT05929066	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight	Obesity, Overweight	Phase 3	Completed	2335
NCT04823208	A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)	Diabetes Mellitus, Type 2	Phase 1	Completed	64
NCT04881760	A Study of LY3437943 in Participants Who Have Obesity or Are Overweight	Obesity, Overweight	Phase 2	Completed	338
NCT06982846	A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia	Type 2 Diabetes Mellitus	Phase 1	Completed	80
NCT05929079	A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight	Type 2 Diabetes, Obesity	Phase 3	Running, closed to new participants	1000
NCT05882045	A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease	Obesity, Cardiovascular Diseases	Phase 3	Running, closed to new participants	1946
NCT07035093	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain	Obesity, Overweight	Phase 3	Running, closed to new participants	586
NCT06662383	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity	Obesity	Phase 3	Running, closed to new participants	800
NCT06383390	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	Phase 3	Running, closed to new participants	10000
NCT06260722	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	Diabetes Mellitus, Type 2	Phase 3	Running, closed to new participants	1250
NCT07232719	A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight	Obesity, Overweight	Phase 3	Running, closed to new participants	250
NCT06859268	A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity	Obesity	Phase 3	Running, closed to new participants	643
NCT06982859	A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus	Diabetes Mellitus, Insulin Sensitivity	Phase 1	Running, closed to new participants	95
NCT06297603	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)	Type 2 Diabetes	Phase 3	Running, closed to new participants	320
NCT07357415	A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight	Obesity, Overweight	Phase 3	Running, closed to new participants	600

—Read this

A trial count is not a verdict

These numbers describe how much has been formally studied in humans, not whether something works or is safe for you. A compound can be tested for one condition and sold for another — which is usually the story. This page is automated aggregation from public registries; no physician has reviewed it. Take anything here to a clinician.

Common questions about Retatrutide

How many human trials does Retatrutide have?

33. That is the number of registered interventional human studies we can find, each listed on this page with a link to its original record.

Is Retatrutide FDA approved?

No. Retatrutide is not approved by the FDA for any indication. Compounded or "research use only" preparations are not FDA-approved and receive no premarket review for safety, effectiveness, or manufacturing quality.

What is Retatrutide actually being tested for?

Registered studies cover: obesity, metabolic dysfunction-associated steatotic liver disease, body composition. Compare that to what it is marketed for — the two lists are often different, which is the whole point of this page.

Where does this data come from?

ClinicalTrials.gov, the US public registry of clinical studies. We count interventional human studies only — observational studies are not evidence of effect. Every trial on this page links to its original record so you can check us rather than trust us.